Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03270514 · ClinicalTrials.gov registry record · Phase 3

Comparison of Sternal Wound Infiltration With Liposomal Bupivacaine v. Bupivacaine Hydrochloride

A Phase 3 study of Coronary Artery Disease and Valve Regurgitation, Mitral, sponsored by Kathirvel Subramaniam.

Completed
Registry status
Phase 3
Development phase
60
Enrollment target
1
Study location

NCT03270514 is a Phase 3 study of Coronary Artery Disease and Valve Regurgitation, Mitral that has completed, run by Kathirvel Subramaniam. The registered enrollment target is 60 participants, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03270514, a Phase 3 study of Coronary Artery Disease and Valve Regurgitation, Mitral, has completed, sponsored by Kathirvel Subramaniam.

COMPLETED
Registry status
Phase 3
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

The aim of this study is to evaluate the analgesic efficacy and safety of wound infiltration with liposomal bupivacaine (LB) in patients undergoing cardiac surgery with sternotomy and cardiopulmonary bypass (CPB) and compare it with bupivacaine hydrochloride infiltration

Interventions

  • DRUG Bupivacaine Hydrochloride
  • DRUG Exparel Injectable Product

Study Locations (1)

Pennsylvania

  • UPMC Presbyterian Hospital - Pittsburgh

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2018-11-15
Est. Completion 2020-02-25
Phase Phase 3

Sponsor

Kathirvel Subramaniam

5 total trials

What the Registry Record Tells You About NCT03270514

The ClinicalTrials.gov registry entry for NCT03270514 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (95% lower). The listed sponsor is Kathirvel Subramaniam, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Coronary Artery Disease appearing as the primary indexed condition, and to 2 interventions - of which Bupivacaine Hydrochloride is the first listed.

NCT03270514 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT03270514 about?

NCT03270514 is a clinical study titled "Comparison of Sternal Wound Infiltration With Liposomal Bupivacaine v. Bupivacaine Hydrochloride". The aim of this study is to evaluate the analgesic efficacy and safety of wound infiltration with liposomal bupivacaine (LB) in patients undergoing cardiac surgery with sternotomy and cardiopulmonary bypass (CPB) and compare it with bupivacaine hydrochloride infiltration

What is the current status of trial NCT03270514?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2018-11-15. Estimated completion is 2020-02-25.

What conditions does trial NCT03270514 study?

This clinical trial studies the following conditions: Coronary Artery Disease, Valve Regurgitation, Mitral, Coronary Artery Stenoses, Valve Regurgitation, Tricuspid.

What interventions are being tested in trial NCT03270514?

The interventions under investigation include: Bupivacaine Hydrochloride (DRUG), Exparel Injectable Product (DRUG).

Who is sponsoring clinical trial NCT03270514?

This trial is sponsored by Kathirvel Subramaniam, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03270514 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Coronary Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.